From bench to bedside: potential of translational research in COVID-19 and beyond DOI
Nityendra Shukla, Uzma Shamim, Preeti Agarwal

et al.

Briefings in Functional Genomics, Journal Year: 2023, Volume and Issue: 23(4), P. 349 - 362

Published: Nov. 20, 2023

Abstract The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and disease 2019 (COVID-19) have been around for more than 3 years now. However, due to constant viral evolution, novel variants are emerging, leaving old treatment protocols redundant. As options dwindle, infection rates continue rise seasonal surges become progressively common across the world, rapid solutions required. With genomic proteomic methods generating enormous amounts of data expand our understanding SARS-CoV-2 biology, there is an urgent requirement development therapeutic that can allow translational research flourish. In this review, we highlight current state COVID-19 in world effects post-infection sequelae. We present contribution COVID-19, with various approaches, including antivirals, monoclonal antibodies vaccines, as well alternate such immunomodulators, currently being studied reiterate importance strategies contain COVID-19.

Language: Английский

mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy DOI Creative Commons
Dariush Haghmorad, Majid Eslami,

Niloufar Orooji

et al.

Frontiers in Bioengineering and Biotechnology, Journal Year: 2025, Volume and Issue: 13

Published: March 12, 2025

The advent of mRNA vaccines, accelerated by the global response to COVID-19 pandemic, marks a transformative shift in vaccine technology. In this article, we discuss development, current applications, and prospects vaccines for both prevention treatment infectious diseases oncology. By leveraging capacity encode antigens within host cells directly, provide versatile scalable platform suitable addressing broad spectrum pathogens tumor-specific antigens. We highlight recent advancements design, innovative delivery mechanisms, ongoing clinical trials, with particular emphasis on their efficacy combating diseases, such as COVID-19, Zika, influenza, well emerging potential cancer immunotherapy. also address critical challenges, including stability, optimization immune responses, broader issue accessibility. Finally, review strategies advancing next-generation aim overcoming limitations technology enhancing preventive therapeutic approaches oncological diseases.

Language: Английский

Citations

1
Metformin Therapy Changes Gut Microbiota Alpha-Diversity in COVID-19 Patients with Type 2 Diabetes: The Role of SARS-CoV-2 Variants and Antibiotic Treatment DOI Creative Commons
Pavlo Petakh, Iryna Kamyshna, Valentyn Oksenych

et al.

Pharmaceuticals, Journal Year: 2023, Volume and Issue: 16(6), P. 904 - 904

Published: June 20, 2023

The gut microbiota play a crucial role in maintaining host health and have significant impact on human disease. In this study, we investigated the alpha diversity of COVID-19 patients analyzed variants, antibiotic treatment, type 2 diabetes (T2D), metformin therapy composition diversity. We used culture-based method to analyze calculated alpha-diversity using Shannon H' Simpson 1/D indices. collected clinical data, such as length hospital stay (LoS), C-reactive protein (CRP) levels, neutrophil-to-lymphocyte ratio. found that with T2D had significantly lower than those without T2D. Antibiotic use was associated reduction alpha-diversity, while an increase. did not find differences between Delta Omicron groups. stay, CRP NLR showed weak moderate correlations Our findings suggest diverse may benefit Interventions preserve or restore diversity, avoiding unnecessary use, promoting therapy, incorporating probiotics, improve patient outcomes.

Language: Английский

Citations

17
Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study DOI Creative Commons
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(1), P. 112 - 112

Published: Jan. 12, 2024

This study investigates the intricate interplay between Metabolic-associated Fatty Liver Disease (MAFLD) and COVID-19, exploring impact of MAFLD on disease severity, outcomes, efficacy antiviral agent Paxlovid (nirmatrelvir/ritonavir). MAFLD, affecting a quarter global population, emerges as potential risk factor for severe yet underlying pathophysiological mechanisms remain elusive. focuses clinical significance Paxlovid, first orally bioavailable granted Emergency Use Authorization in United States. Notably, outcomes from phase II/III trials exhibit an 88% relative reduction COVID-19-associated hospitalization or mortality among high-risk patients. Despite conflicting data association COVID-19 this research strives to bridge gap by evaluating effectiveness patients with addressing scarcity relevant studies.

Language: Английский

Citations

6
Genomic insight into COVID-19 severity in MAFLD patients: a single-center prospective cohort study DOI Creative Commons
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna

et al.

Frontiers in Genetics, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 4, 2024

This study investigated the influence of single nucleotide polymorphisms (SNPs) in genes associated with interferon pathway (IFNAR2 rs2236757), antiviral response (OAS1 rs10774671, OAS3 rs10735079), and viral entry (ACE2 rs2074192) on COVID-19 severity their association nonalcoholic fatty liver disease (MAFLD). We did not observe a significant between SNPs severity. While IFNAR2 rs2236757 A allele was correlated higher creatinine levels upon admission G lower band neutrophils discharge, these findings require further investigation. The distribution OAS gene (rs10774671 rs10735079) differ MAFLD patients non-MAFLD patients. Our population's ACE2 rs2074192 genotypes alleles differed from that European reference population. Overall, our suggest specific may be major contributors to patient population, highlighting potential role other genetic factors environmental influences.

Language: Английский

Citations

6
Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis DOI Creative Commons
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna

et al.

Viruses, Journal Year: 2023, Volume and Issue: 15(8), P. 1724 - 1724

Published: Aug. 12, 2023

Metabolic-associated fatty liver disease (MAFLD) and its potential impact on the severity of COVID-19 have gained significant attention during pandemic. This review aimed to explore genetic determinants associated with MAFLD, previously recognized as non-alcoholic (NAFLD), their influence outcomes. Various polymorphisms, including PNPLA3 (rs738409), GCKR (rs780094), TM6SF2 (rs58542926), LYPLAL1 (rs12137855), been investigated in relation MAFLD susceptibility progression. Genome-wide association studies meta-analyses revealed associations between these variants risk, well effects lipid metabolism, glucose regulation, function. Furthermore, emerging evidence suggests a possible connection MAFLD-associated polymorphisms COVID-19. Studies exploring indicated outcomes shown conflicting results. Some observed protective effect certain against severe COVID-19, while others reported no associations. highlights importance understanding implications for Further research is needed elucidate precise mechanisms linking develop gene profiling tools early prediction If confirmed severity, could aid identification high-risk individuals improving management

Language: Английский

Citations

13
Modulatory Roles of AHR, FFAR2, FXR, and TGR5 Gene Expression in Metabolic-Associated Fatty Liver Disease and COVID-19 Outcomes DOI Creative Commons
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna

et al.

Viruses, Journal Year: 2024, Volume and Issue: 16(6), P. 985 - 985

Published: June 19, 2024

Metabolic-associated fatty liver disease (MAFLD) is a risk factor for severe COVID-19. This study explores the potential influence of gut hormone receptor and immune response gene expression on COVID-19 outcomes in MAFLD patients.

Language: Английский

Citations

5
The influence of genetic polymorphisms on cytokine profiles in pediatric COVID-19: a pilot study DOI Creative Commons
Kateryna Kozak, Halyna Pavlyshyn, Oleksandr Kamyshnyi

et al.

Frontiers in Pediatrics, Journal Year: 2025, Volume and Issue: 13

Published: Feb. 24, 2025

Recent studies have underscored the importance of genetic factors in predicting COVID-19 susceptibility and severity. While cytokine storms are crucial disease severity, predisposition significantly influences immune responses. Our study examined genes related to SARS-CoV-2 invasion (ACE2 rs2074192) interferon-induced immunity (IFNAR2 rs2236757, TYK2 rs2304256, OAS1 rs10774671, OAS3 rs10735079). Additionally, we investigated linked Kawasaki (CD40 rs4813003, FCGR2A rs1801274, CASP3 rs113420705) that play roles immunogenesis. The pilot study, which involved 75 pediatric patients aged one month 17 years [43 with active COVID-19, children multisystem inflammatory syndrome (MIS-C), 15 healthy controls], was conducted Ternopil, Ukraine. Gene polymorphism studied for all patients. ELISA kits were used interleukin studies, including Human IL-1β (Interleukin 1 Beta), IL-6 6), IL-8 8), IL-12 12), IFN-α (Interferon Alpha), TNF-α (Tumor Necrosis Factor Alpha). Statistical analysis performed using IBM SPSS Statistics 21 GraphPad Prism 8.4.3. identified significant gene-cytokine associations ACE2 rs2074192 T allele correlated increased IL-1β, IL-6, IL-8, TNF-α. IFNAR2 rs2236757 A elevated levels low levels, while rs10774671 carriers also exhibited lower levels. prognostically determining infected SARS-CoV-2. gene rs10735079 associated changes precisely a high level. CD40 rs4813003 C had higher IL-12. results our revealed correlation between rs1801274 (A/G). rs113420705 led an increase IL-6. These findings enhance understanding may hold promise developing targeted interventions providing personalized medical approach each patient.

Language: Английский

Citations

0
Evaluation of the duration of new nasal drug interferon α-2b activity in an experimental model system DOI Creative Commons
Natalia Bezdieniezhnykh, O Lykhova,

G. I. Borshchevskіy

et al.

Virology Journal, Journal Year: 2025, Volume and Issue: 22(1)

Published: April 10, 2025

To develop an adequate system for assessing the duration of IFN antiviral activity in nasal cavity animals and to study a new drug form gel comparison with known spray form. assess specific IFN, drugs were administered into experimental rats. One, 3, 4 h after administration, cavities rats washed out, from (WNC) was analyzed vitro. Developed algorithm preparations using sensitive vitro test system, which analysis WNC made it possible detect administration forms IFN-a variant spray. It established that 1 intranasal same concentration is: 266.8 ± 14.0 IU/ml IFN/spray 260.2 20.9 IU/ ml IFN/gel. Three hours are administered, their decreases but remains at sufficiently high level: 121.4 5.4 88.3 6.2 Four IFN/gel significantly greater than IFN/spray: 39.4 4.9 10.6 1.0 IU/ml, respectively. The developed evaluating allows local effect drugs. persisted administration: on walls

Language: Английский

Citations

0
The Relationship between COVID-19 Severity in Children and Immunoregulatory Gene Polymorphism DOI Creative Commons
Kateryna Kozak, Halyna Pavlyshyn, Oleksandr Kamyshnyi

et al.

Viruses, Journal Year: 2023, Volume and Issue: 15(10), P. 2093 - 2093

Published: Oct. 14, 2023

Coronavirus disease (COVID-19) and its outcomes remain one of the most challenging problems today. COVID-19 in children could be asymptomatic, but can result a fatal outcome; therefore, predictions severity are important. The goal was to investigate human genetic factors that associated with children. Single-nucleotide polymorphisms following genes were studied: ACE2 (rs2074192), IFNAR2 (rs2236757), TYK2 (rs2304256), OAS1 (rs10774671), OAS3 (rs10735079), CD40 (rs4813003), FCGR2A (rs1801274) CASP3 (rs113420705). In case-control study 30 mild or moderate course disease; severe symptoms multisystem inflammatory syndrome (MIS-C) 15 who healthy, did not have SARS-CoV-2 (PCR negative, Ig G negative). revealed rs2074192 (allele T), rs2236757 A), rs10774671 rs4813003 C), rs113420705 C) male sex contribute MIS-C 85.6% cases. World Health Organization reported new variants may cause previously unseen Although has limitations due cohort size, findings help provide better understanding infection proactive pediatric patient management.

Language: Английский

Citations

10
Modulatory Roles of AHR, FFAR2, FXR, and TGR5 Gene Expression in MAFLD and COVID-19 Outcomes DOI Open Access
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna

et al.

Published: May 13, 2024

Metabolic-associated fatty liver disease (MAFLD) is a risk factor for severe COVID-19. This study explores the potential influence of gut hormone receptor and immune response gene expression on COVID-19 outcomes in MAFLD patients. Methods: We investigated levels AHR, FFAR2, FXR, TGR5 patients with compared to controls. examined associations between clinical outcomes. Results: displayed altered AHR expression, potentially impacting recovery. Downregulated correlated increased coagulation parameters. Elevated FFAR2 linked specific cell populations hospital stay duration. Significantly lower FXR was observed both Conclusion: Our findings suggest modulatory roles MAFLD.

Language: Английский

Citations

3